Hepatology:中科大田志刚教授团队揭示以天然免疫为主导的HBV相关肝癌发病机制

2018-11-05 疫苗 病毒学界

最近,肝病权威学术期刊Hepatology杂志在线发表了中国科技大学生命科学院田志刚教授团队的研究成果,揭示了天然免疫应答在HBV相关肝细胞癌(HCC)发生中的重要作用。

最近,肝病权威学术期刊Hepatology杂志在线发表了中国科技大学生命科学院田志刚教授团队的研究成果,揭示了天然免疫应答在HBV相关肝细胞癌(HCC)发生中的重要作用。

乙型肝炎病毒(HBV)是肝细胞癌(HCC)的重要危险因素,目前研究认为,除插入突变和病毒蛋白对宿主基因的激活和反式激活以及其他一些因素外,慢性肝脏损伤和组织再生是导致肝细胞恶性变和发生HCC的重要诱因。但HBV是非细胞毒性病毒,本身并不引起肝细胞损伤,HBV感染时的肝脏损伤主要是由于机体的抗HBV免疫应答引起,因此,免疫应答相关的病理机制对于HBV相关性HCC的发生至关重要。但天然免疫应答在此过程中有何作用并不清楚。

在既往的研究中,团队曾发现天然免疫系统中的重要组分,NK细胞,在HBV感染时除发挥抗病毒作用外,也参与了肝细胞的损伤。而IFN-γ是其中的重要分子。

在最新发表的这项研究中,研究者给小鼠注射了NK细胞活化剂poly(I∶C),剂量为3 μg/g,2次/周,共8周。6个月后,所有注射了poly(I∶C)的12~13月龄的HBV转基因(HBs-Tg)小鼠均发生了HCC,发生率达100%,野生型小鼠均未出现HCC。而未经处理的HBs-Tg小鼠中HCC的自然发生率为16.7%(12~13月龄)和40%(24~25月龄)。这提示活化的NK细胞加速了HBV转基因小鼠中HCC的发生发展。

poly(I∶C)处理的HBs-Tg小鼠肝内发生炎症和肝细胞损伤,可观察到淋巴细胞浸润显着增加,伴有肝细胞的凋亡和增殖同时增加,肝细胞的上皮-间充质转化(EMT)加快。研究证实,该模型中的细胞EMT和肿瘤生成依赖于NK细胞--如果去除NK细胞,则HCC发生率显着降低为28.6%。

而进一步研究发现,肝内的NK细胞高表达IFN-γ,抗-IFN单克隆中和抗体也许可明显减轻肝炎,肝细胞特异性的IFN-γ表达促进了HCC的发生。如果缺乏IFN-γ,即便有肝脏NK细胞并且被激活,HCC的发生仍可被阻止,提示IFN-γ在NK细胞介导的肿瘤发生中扮演了核心的角色。

原始出处:Yongyan Chen, Xiaolei Hao, Rui Sun, et al. NK cell‐derived IFN‐γ promotes hepatocellular carcinoma through EpCAM‐EMT axis in hepatitis B virus transgenic mice. Hepatology. 17 October 2018 

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799851, encodeId=e5fc1e9985167, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Dec 05 07:42:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664797, encodeId=e7e91664e97fa, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Aug 06 16:42:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836673, encodeId=7b2f18366e3cf, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon May 13 13:42:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427257, encodeId=bbac142e25768, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481291, encodeId=87f21481291d9, content=<a href='/topic/show?id=c5534414ee6' target=_blank style='color:#2F92EE;'>#天然免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44147, encryptionId=c5534414ee6, topicName=天然免疫)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799851, encodeId=e5fc1e9985167, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Dec 05 07:42:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664797, encodeId=e7e91664e97fa, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Aug 06 16:42:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836673, encodeId=7b2f18366e3cf, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon May 13 13:42:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427257, encodeId=bbac142e25768, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481291, encodeId=87f21481291d9, content=<a href='/topic/show?id=c5534414ee6' target=_blank style='color:#2F92EE;'>#天然免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44147, encryptionId=c5534414ee6, topicName=天然免疫)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799851, encodeId=e5fc1e9985167, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Dec 05 07:42:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664797, encodeId=e7e91664e97fa, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Aug 06 16:42:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836673, encodeId=7b2f18366e3cf, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon May 13 13:42:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427257, encodeId=bbac142e25768, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481291, encodeId=87f21481291d9, content=<a href='/topic/show?id=c5534414ee6' target=_blank style='color:#2F92EE;'>#天然免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44147, encryptionId=c5534414ee6, topicName=天然免疫)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
    2019-05-13 klivis
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799851, encodeId=e5fc1e9985167, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Dec 05 07:42:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664797, encodeId=e7e91664e97fa, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Aug 06 16:42:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836673, encodeId=7b2f18366e3cf, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon May 13 13:42:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427257, encodeId=bbac142e25768, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481291, encodeId=87f21481291d9, content=<a href='/topic/show?id=c5534414ee6' target=_blank style='color:#2F92EE;'>#天然免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44147, encryptionId=c5534414ee6, topicName=天然免疫)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
    2018-11-07 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799851, encodeId=e5fc1e9985167, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Wed Dec 05 07:42:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664797, encodeId=e7e91664e97fa, content=<a href='/topic/show?id=01b422336b1' target=_blank style='color:#2F92EE;'>#中科大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22336, encryptionId=01b422336b1, topicName=中科大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07fc25842240, createdName=ms7019579240139182, createdTime=Tue Aug 06 16:42:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836673, encodeId=7b2f18366e3cf, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Mon May 13 13:42:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427257, encodeId=bbac142e25768, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481291, encodeId=87f21481291d9, content=<a href='/topic/show?id=c5534414ee6' target=_blank style='color:#2F92EE;'>#天然免疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44147, encryptionId=c5534414ee6, topicName=天然免疫)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Wed Nov 07 10:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]

相关威廉亚洲官网

J Med Chem:一类具有新作用机制的选择性口服小分子HBV抑制剂

近日科学家报道了二氢喹诺酮(DHQ)衍生物的抗HBV活性以及构效关系,其中化合物RG7834是一种具有高度选择性和口服生物活性的乙肝病毒抑制剂,它能抑制病毒抗原和病毒的DNA活性,而且具有新的作用机制。

J Hepatol:DAA治疗对肝移植的影响:对适应症和结果演变的影响

在欧洲,引入DAA治疗后,由HCV相关肝脏疾病(失代偿性肝硬化和HCC)而进行肝移植的比例较利巴韦林时代,显著下降;与此同时,进行肝移植的患者的3年生存率,得到了改善。

J Viral Hepat:丙型肝炎患者的神经精神症状与自身免疫性肝病患者相似但与乙型肝炎患者的神经精神状态不同

HCV患者的神经精神病学特征与AIH和PBC患者相似,但与HBV患者不同,提示自身免疫反应可能是这些差异的原因之一。

Blood:预防性核苷类似物治疗可降低乙肝复发风险

中心点:在抗CD20免疫疗法治疗B细胞NHL的过程中,HBV DNA监测引导的抢占式核苷疗法可预防HBV肝炎。预防性核苷疗法可预防HBV再活化,适用于高风险患者。摘要:3期GOYA和GALLIUM研究,对采用包含obinutuzumab或利妥昔单抗的免疫化学疗法治疗的并发HBV感染并已被治愈(乙型肝炎表面抗原阴性、乙型肝炎核心抗体阳性)的B细胞非霍奇金淋巴瘤(NHL)患者HBV再活化的风险进行评估

J Viral Hepat:慢性乙肝病毒感染患者的血清HBV-RNA自然史

在慢性乙肝病毒感染的自然过程中,HBV-RNA的基线水平和病毒复制中间产物的构成有显著差异。

世界肝炎日:聚焦肝炎三大热点

7月28日是第8个“世界肝炎日”,WHO将活动主题定为“检测治疗肝炎”, 大力宣传“及时检测,及时治疗,及时治愈”的理念。在世界肝炎日到来之际,记者采访了中华医学会肝病学分会副主任委员、河北医科大学第三医院中西医结合肝病科主任南月敏教授,请她就乙肝病毒(HBV)母婴阻断、丙肝防治和药物性肝损伤(DILI)肝炎领域三大热点问题进行分享。